Therillume is a therapeutics company with a focus on glioblastoma and Neurofibromatosis Type 1 and 2. Therillume is spinning out from Recombinetics, leveraging its gene-editing platform to identify, validate & expedite therapeutic candidates through clinical development. Therillume has amassed a powerful consortium of KOL’s and leading institutions to advance novel and innovative therapies in neuro-oncology. We expect to enter the clinic in 2023.